Condition

EGFR Gene Mutation

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 54 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials54

Recruiting12

Common interventions25

Lead sponsors shown15

Clinical trials

54 shown

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based ChemotherapyNCT07548060 · 2026-02-01

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx PopulationsNCT06716580 · 2025-04-01

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CTNCT06222489 · 2025-03-03

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal MetastasisNCT06643000 · 2024-12-20

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsNCT06071013 · 2024-02-23

Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.NCT06238882 · 2023-02-23

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung AdenocarcinomaNCT05503667 · 2022-02-01

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)NCT05598528 · 2021-09-28

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain MetastasesNCT05033691 · 2021-03-09

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationNCT04322890 · 2020-04-16

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsNCT03175224 · 2017-09-27

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI TherapyNCT03042221 · 2016-05-10

In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity TestingNCT07697716 · 2026-09-01

NOT_YET_RECRUITING

An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver MetastasesNCT07461727 · 2026-02-10

NOT_YET_RECRUITING

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLCNCT06436144 · 2024-06-01

NOT_YET_RECRUITING

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLCNCT06300424 · 2024-04-01

ACTIVE_NOT_RECRUITING

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)NCT06323148 · 2024-04-01

NOT_YET_RECRUITING

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLCNCT06117644 · 2023-11-01

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.NCT06018688 · 2023-09-15

A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLCNCT05698264 · 2023-01-20

NOT_YET_RECRUITING

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted TherapiesNCT05370469 · 2022-08-25

ACTIVE_NOT_RECRUITING

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)NCT04908956 · 2022-08-04

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLCNCT05394233 · 2022-06-01

Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung CancerNCT05517083 · 2022-04-01

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLCNCT05153408 · 2022-01-13

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib TreatmentNCT04882345 · 2021-07-15

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCNCT04862780 · 2021-06-29

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 MutationsNCT04695925 · 2021-03-29

ACTIVE_NOT_RECRUITING

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated PatientsNCT04512430 · 2020-12-02

Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC PatientsNCT04552613 · 2020-11-23

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung CancerNCT04592666 · 2020-10-09

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung AdenocarcinomaNCT04201756 · 2020-07-26

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI TherapyNCT05314296 · 2020-06-01

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With GefitinibNCT04358562 · 2020-05-01

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLCNCT04206072 · 2019-12-24

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung CancerNCT04085315 · 2019-11-12

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted TherapiesNCT04042558 · 2019-09-26

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung CancerNCT04013542 · 2019-09-13

ACTIVE_NOT_RECRUITING

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT03909334 · 2019-07-25

ACTIVE_NOT_RECRUITING

First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung CancerNCT06521034 · 2019-06-27

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.NCT03755102 · 2018-11-21

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) MetastasesNCT03653546 · 2018-10-29

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung CancerNCT03396185 · 2018-05-09

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung CancerNCT02947386 · 2017-06-29

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475NCT03049618 · 2017-03-10

Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLCNCT03046992 · 2017-02-15

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismNCT03002844 · 2016-12-01

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR MutationsNCT02954523 · 2016-10-01

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNANCT02629523 · 2016-06-01

Metformin Plus TKI Use in Patients With Non-Small Cell Lung CarcinomaNCT03071705 · 2016-03-01

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With AfatinibNCT04640870 · 2015-03-15

Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)NCT02338011 · 2014-11-01

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung CancersNCT02098954 · 2014-07-01

Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer PatientsNCT03171636 · 2014-04-01

Common interventions

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

osimertinib12 carboplatin5 pemetrexed4 afatinib3 gefitinib3 bevacizumab2 alectinib 150 MG1 aspirin1 atezolizumab1 crizotinib 250 MG1 dacomitinib1 dasatinib1 erlotinib1 metformin1 paclitaxel protein-bound1 ramucirumab1

Leading sponsors

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 3 Shanghai Pulmonary Hospital, Shanghai, China 3 Betta Pharmaceuticals Co., Ltd. 2 Blueprint Medicines Corporation 2 Fudan University 2 Hunan Province Tumor Hospital 2 Instituto Nacional de Cancerologia de Mexico 2 Shanghai Chest Hospital 2 Alpha Biopharma (Jiangsu) Co., Ltd. 1 Apollomics Inc. 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences 1 Centre Francois Baclesse 1 China Medical University Hospital 1 Chonnam National University Hospital 1 Chul Kim 1

Trial status mix

COMPLETED15

RECRUITING12

UNKNOWN12

ACTIVE_NOT_RECRUITING5

NOT_YET_RECRUITING5

TERMINATED5

Phase mix

PHASE229

PHASE110

NA9

PHASE35

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.